Arsenous Acid for Refractory Triple-Negative Breast Cancer
Status:
RECRUITING
Trial end date:
2026-10-23
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the progression-free survival (PFS) and safety of arsenous acid in combination with palliative chemotherapy for refractory triple-negative breast cancer following multiple lines of treatment.